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Abstract
Background—Endoscopic mucosal resection (EMR) is commonly performed before
radiofrequency ablation (RFA) for nodular dysplastic Barrett’s esophagus (BE).
Objective—To determine the efficacy and safety of EMR before RFA for nodular BE with
advanced neoplasia (high-grade dysplasia (HGD) or intramucosal carcinoma (IMC)).
Design—Retrospective study.
Setting—University of North Carolina Hospitals, from 2006 to 2011.
Patients—169 patients with BE with advanced neoplasia – 65 patients treated with EMR and
RFA for nodular disease and 104 patients treated with RFA alone for non-nodular disease.
Interventions—Endoscopic mucosal resection, radiofrequency ablation.
Main Outcome Measurements—Efficacy (complete eradication of dysplasia, complete
eradication of intestinal metaplasia, total treatment sessions, RFA treatment sessions), safety
(stricture formation, bleeding, and hospitalization).
Results—EMR followed by RFA achieved complete eradication of dysplasia and complete
eradication of intestinal metaplasia in 94.0% and 88.0%, respectively, compared with 82.7% and
77.6%, respectively in the RFA only group (p=0.06 and p=0.13, respectively). The complication
rates between the two groups were similar (7.7% vs. 9.6%, p=0.79). Strictures occurred in 4.6% of
patients in the EMR before RFA group compared with 7.7% of patients in the RFA only group
(p=0.53).
Limitations—Retrospective study at a tertiary-care referral center.
Conclusion—In patients treated with EMR before RFA for nodular BE with HGD or IMC, no
differences in efficacy and safety outcomes were observed compared with RFA alone for non-
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nodular BE with HGD or IMC. EMR followed by RFA is safe and effective for patients with
nodular BE and advanced neoplasia.
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Introduction
Barrett’s esophagus (BE) is a precancerous condition associated with adenocarcinoma of the
esophagus,1, 2 a condition with a marked increase in incidence over the past four decades.3, 4
BE with high-grade dysplasia (HGD) may progress to adenocarcinoma in as many as 20%
of patients per year.5 Similarly, BE with intramucosal carcinoma (IMC) is a high risk lesion
in the absence of disease-altering therapy. Radiofrequency ablation (RFA) is a safe and
effective therapy for the eradication of non-nodular dysplastic BE.5-7 However, many
patients with HGD or IMC have nodularity in their Barrett’s segment. Endoscopic mucosal
resection (EMR) is commonly performed to remove these nodular areas before treatment
with RFA.8, 9 Despite being frequently performed, the safety and efficacy of RFA after
EMR is poorly understood.
The aims of this study were to compare the safety and efficacy of combined EMR/RFA
treatment for nodular Barrett’s to treatment with RFA alone for non-nodular Barrett’s. We
assessed whether preceding EMR leads to either a higher complication rate or decreased
efficacy compared to subjects requiring RFA alone.
Methods
Patient eligibility and data collection
We performed a retrospective study of adult patients treated with RFA for BE with HGD or
IMC at University of North Carolina (UNC) Hospitals between 2006 and 2011. Subjects
were identified by review of our electronic endoscopic database (Provation MD, Wolters
Kluwer, Minneapolis, MN) from January 1, 2006 through November 1, 2011 using the
following terms: Barrett, esophageal adenocarcinoma, cancer, carcinoma in situ, dysplasia,
ablation, radiofrequency. We also performed a search using a procedure code for
esophagoscopy with ablation (CPT 43228).
Each subject was then reviewed by one of two investigators (HK, WB) using the electronic
medical record (WebCIS, University of North Carolina Health Care System) to determine
eligibility for inclusion. Patients were excluded if they never received treatment with RFA,
were treated with RFA for a non-BE related disease, did not have a pre-ablation histology of
HGD or IMC, or underwent EMR after RFA initiation. All eligible patients were included in
the safety analysis, whereas the efficacy analysis excluded individuals receiving ongoing
RFA therapy as of November 1, 2011.
Pertinent data were extracted from clinical, endoscopy, and pathology reports for each
subject and included demographic information (age, gender, race, body mass index (BMI)),
pertinent medical history (erosive esophagitis, peptic stricture), substance use (alcohol,
tobacco), medication use (anti-secretory therapy, non-steroidal anti-inflammatory drugs
(NSAID)), EGD findings (length of BE, Prague C and M classification, hiatus hernia,
erosions, ulcers, nodules), pre-ablation histology, treatment provided, ablation outcomes,
and complications. At all treatment sessions, patients provided interim history regarding any
complications of therapy or visits to other institutions for treatment-related issues. To
standardize methodology, the first ten subjects were reviewed by both investigators jointly
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with discrepancies in data collection resolved by consensus. For additional quality control,
every 20th study subject was reviewed independently by both investigators to assess inter-
rater agreement of abstracted data.
Pre-treatment evaluation and procedural protocol
All patients had an initial consultation visit to discuss BE and dysplasia, its risk of
progression to cancer, and the risks and benefits of different treatment options including
continued endoscopic surveillance, ablative therapy, and esophagectomy. Worst histologic
grade of BE was determined by review of original pathology records. All cases were
reviewed by an expert gastrointestinal pathologist as part of routine care, and if findings
between the initial pathology report and the secondary review were discordant, an additional
expert gastrointestinal pathologist reviewed the case with histologic classification by
consensus.
Patients who opted for RFA had pre-treatment staging by EGD and EUS to exclude invasive
or metastatic disease that would preclude curative endoscopic treatment. If the BE segment
had no visible mucosal abnormalities, RFA was performed as outlined below. If the BE
segment contained any mucosal abnormality with the exclusion of deep ulceration, EMR
was performed before the beginning of RFA therapy. Nodules were defined endoscopically
as any contoured irregularity and elevation of the mucosa without breaks, including Paris
classification 0-I and 0-IIa lesions.10 All visible lesions were resected endoscopically using
either the Olympus 18 mm oblique cap kit (Olympus America, Center Valley, PA) or the
Duette device (Cook Medical, Winston-Salem, NC). EMR performed with the Olympus
device was preceded by submucosal injection of saline solution, whereas EMR with the
Duette device was performed without prior injection. RFA therapy was initiated two months
after all visible lesions were removed and if pathology specimens did not reveal submucosal
infiltration of adenocarcinoma. Twice daily proton pump inhibitor therapy was prescribed to
all patients before and throughout RFA treatment.
Patients with circumferential disease were treated with circumferential RFA using the
HALO360 device, whereas focal lesions were treated with focal RFA using the HALO90
device (BARRX Medical, Sunnyvale, CA). Standard procedural technique was used as
previously described.6 Patients returned every two months for repeat EGD to assess
treatment response, and residual BE was treated with focal ablation until no visible BE was
observed on white-light and narrow band imaging endoscopy. At this point, four-quadrant
biopsies were taken from just distal to the gastroesophageal junction and at 1 cm intervals
along the length of the original BE segment. Treatment was considered complete and
successful if the subject displayed no endoscopic or histological evidence of residual
intestinal metaplasia in the tubular esophagus.
Outcomes and statistical analysis
Safety outcomes included death, esophageal perforation, stricture formation, bleeding, and
hospitalization. A stricture was defined as any narrowing of the esophageal lumen that was
treated with dilation, regardless of symptoms of dysphagia. Bleeding was considered
clinically significant if it required a blood transfusion or hospitalization. Safety outcomes
were described for patients who received EMR before RFA and for subjects who received
RFA only, and were reported per patient and per procedure, relative to the total number of
treatment sessions.
Upon completion of endoscopic therapy, all biopsy specimens were reviewed by an expert
gastrointestinal pathologist to determine the presence of residual BE and degree of
dysplasia. Any specimen demonstrating dysplasia was confirmed with a second histological
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analysis by a second GI pathologist. Assessment of RFA efficacy included complete
eradication of dysplasia (CED), complete eradication of intestinal metaplasia (CEIM), total
treatment sessions, and RFA treatment sessions. CED was defined as the absence of
dysplasia from all esophageal biopsies, and CEIM was defined as complete endoscopic
resolution and the absence of IM from all esophageal biopsies. Total treatment sessions
include any ablation or endosopic mucosal resection treatment, whereas RFA sessions
include only circumferential and focal RFA treatments.
The proportion of subjects achieving CED or CEIM, total treatment sessions, and RFA
sessions are described on an intention-to-treat (ITT) and per protocol (PP) basis. Any patient
who was lost to follow-up, died during the RFA treatment period from an unrelated cause, or
had treatment halted due to an unrelated life-limiting comorbidity was considered a
treatment failure in the ITT analysis. The PP analysis included all subjects in whom
treatment was considered complete. Efficacy outcomes were described for patients who
received EMR before RFA and for subjects who received RFA only.
Statistical analysis was performed using Stata software (version 12.0; StataCorp LP, College
Station, TX). Safety and efficacy outcomes were reported for subjects who had EMR before
RFA and for those who had RFA only, and comparative analyses were performed using the
Student’s t-test or the Wilcoxon rank sum test for continuous variables and the Pearson’s
chi-square test or the Fisher exact test for categorical variables. P-values less than 0.05 were
considered significant. This study was approved by the UNC IRB.
Results
Patient Eligibility
A total of 286 patients received EGD with ablative therapy at UNC hospitals between 2006
and 2011. Of these patients, 117 were excluded: 19 never received RFA and were treated
with a different ablative modality (15 cryoablation, 2 argon plasma coagulation, 2
photodynamic therapy); 5 were treated for a non-BE related disease (3 squamous cell
carcinoma, 1 gastric antral vascular ectasia, 1 gastric cardia dysplasia); 71 had pre-ablation
histology other than HGD or IMC (11 non-dysplastic BE, 53 low-grade dysplasia, 7 invasive
adenocarcinoma); and 22 underwent EMR after the initiation of RFA therapy.
Safety Outcomes
The remaining 169 patients were included in the safety analysis – 65 patients underwent
EMR before RFA and 104 patients received RFA only. The baseline characteristics of these
patients are summarized in Table 1. Patients who had EMR before RFA were older (mean
age 68.8 vs. 64.2, p=0.008) and were more likely to have IMC (43.1% vs. 2.9%, p<0.001)
compared with those who had RFA only.
All patients who underwent EMR before RFA therapy had nodular disease (Paris 0-I and 0-
IIa lesions). These 65 patients underwent a total of 66 EMR sessions with a single patient
having 2 EMR sessions. Fifty-five percent of patients underwent EMR with the Olympus
18mm oblique cap kit and 45% of patients underwent EMR with the Duette device. Sixty-
one percent of patients had one resection performed during the EMR session, whereas 39%
had multiple resections performed. Of those who had multiple resections, subjects
underwent a mean of 2.5 resections during a given EMR session.
Patients in the EMR before RFA group underwent 212 total treatment sessions (3.3 per
patient), and patients receiving RFA only underwent 293 total treatment sessions (2.8 per
patient) (p=0.09). Of patients who received EMR before RFA, 37% received combination
therapy with circumferential and focal ablation and 57% received focal ablation only. Of
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patients who received RFA only, 56% received combination therapy with circumferential
and focal ablation and 36% received focal ablation only.
Complications occurred in 5 of 65 patients (7.7% of patients, 2.4% of procedures) who had
EMR before RFA, compared with 10 of 104 patients (9.6% of patients, 3.4% of procedures)
who had RFA only. There were no deaths or esophageal perforations in either group; all
complications were related to either stricture or bleeding. A stricture occurred in three
patients who had EMR before RFA (4.6% of patients, 1.4% of procedures) compared with
eight patients who had RFA only (7.7% of patients, 2.7% of procedures). All strictures
developed after an RFA treatment session, were <1 cm in length, and resolved after a
median of 1 endoscopic dilation. Of those in the EMR before RFA group, strictures occurred
in 2 patients treated with the Olympus cap, whereas stricture occurred in 1 patient treated
with the Duette device (6% vs. 4%, p=1.00). There were no stricture recurrences in the EMR
before RFA group on subsequent endoscopies. Three patients in the RFA only group had
stricture recurrence, and 2 of these patients required additional intervention with endoscopic
dilation. Post-procedural hemorrhage occurred in 2 patients who had EMR before RFA and
in 2 patients who had RFA only. In those who had EMR before RFA, both patients had post-
procedural hemorrhages after an EMR session. One patient was treated with the Olympus
cap, whereas the other was treated with the Duette device (3% vs. 4%, p=1.00). All 4
patients with post-procedural hemorrhage were subsequently hospitalized – 3 patients were
hospitalized for 1 day each and the fourth patient for 2 days. Complication rates of those
with EMR before RFA versus RFA alone were not statistically different (p>0.05 for all
comparisons, see Table 2).
Efficacy Outcomes
Twenty-one of the 169 patients included in the safety analysis were receiving ongoing RFA
therapy and were excluded from the efficacy analysis. The remaining 148 patients (50 EMR
before RFA, 98 RFA only) were included in the ITT analysis, including 16 patients who did
not complete treatment and were considered treatment failures: 11 were lost to follow-up; 4
were diagnosed with a life-threatening comorbidity unrelated to their esophageal condition,
which precluded further therapy; and 1 died of an unrelated event during the treatment
period. There were no cancer-related deaths in the cohort. Two of the 16 patients who did
not complete treatment belonged to the EMR/RFA group, whereas 14 of them belonged to
the RFA only group (4% EMR/RFA ITT efficacy cohort vs. 14% RFA only ITT efficacy
cohort; p=0.09). The PP analysis included 132 patients (48 EMR before RFA, 84 RFA only)
after excluding the 16 patients who did not complete treatment. The baseline characteristics
for all patients included in the efficacy analysis were similar to the overall cohort, with
patients who had EMR before RFA again older (mean age 68.1 vs. 63.9, p=0.02) and more
likely to have IMC (42.0% vs. 3.1%, p<0.001) compared with those who had RFA only.
CEIM was achieved in 88% ITT (92% PP) who had EMR before RFA compared with 78%
(91% PP) who had RFA only (p>0.05 for both ITT and PP comparisons). CED was achieved
in 94% (98% PP) who had EMR before RFA compared with 83% (96% PP) who had RFA
only (p>0.05 for both ITT and PP comparisons). Disease progression occurred despite
therapy in two patients who had RFA only and in no patients who had EMR before RFA.
There was no clinical or statistical difference in the ability of EMR/RFA to achieve CED
and CEIM compared with RFA alone (Table 3). Compared with RFA alone, EMR/RFA
required more total treatment sessions (mean 3.5 vs. 2.8, p=0.02) to achieve completion, but
no difference in the number of RFA sessions was observed (mean 2.5 vs. 2.8, p=0.28). Prior
EMR was also associated with a decreased number of circumferential ablation sessions
(mean 0.40 vs. 0.67, p=0.003). Mean follow-up to eradication was 9.0 months.
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In this retrospective study, we report the largest series of patients treated with EMR before
RFA, as well as the largest series examining endoscopic treatment of HGD and IMC with
RFA. We compared the safety and efficacy of EMR before RFA for nodular BE with RFA
only for non-nodular BE in adult patients with BE and advanced neoplasia. Both treatment
modalities were found to be effective, and similar rates of CED and CEIM were achieved in
both groups. The two treatment groups also experienced similar rates of complication,
consisting mostly of benign strictures that were successfully treated with endoscopic
dilation. Previous work demonstrated that prior EMR may diminish efficacy of RFA, and
that more extensive EMR results in a 25-37% stricture rate.11-13 However, our work
demonstrates that focal EMR for nodular disease, which is commonly performed in the U.S.,
is not associated with either a decreased likelihood of successful eradication of intestinal
metaplasia or an increased risk of esophageal stricture.
Endoscopic therapy consisting of EMR combined with mucosal ablation has been found to
be an effective treatment modality for BE with advanced neoplasia and visible lesions.14, 15
Although RFA is safe and effective, our understanding of combined therapy consisting of
EMR before RFA for nodular BE is limited. Several case series have been reported by a
European medical center (Amsterdam Medical Center, Netherlands), limited in each
instance by small study populations and the absence of a control group for comparison.16-20
In the largest series published by this center, Pouw et al. performed a study of 44 patients
who had RFA with or without prior EMR, in which 98% of patients achieved CED and
CEIM. Of the 44 patients, 31 of them had prior EMR. Five patients experienced an adverse
event from EMR (4 mild hemorrhages, 1 esophageal perforation), and 4 patients developed
dysphagia after RFA, with all cases occurring in patients who had prior EMR. The lack of
two distinct groups in this publication – those with and those without prior EMR – prevented
examination of the effects of EMR on the safety and efficacy of RFA.18 A second study by
Pouw et al. consisted of 24 patients, of which 23 (96%) had EMR before RFA. CED and
CEIM were achieved in 95% and 88%, respectively, and 8% of patients experienced a
complication, including 1 stricture formation.19
A recent study from the Mayo Clinic (Rochester, MN) directly compared patients who
received RFA after EMR (n=44) versus RFA alone (n=46).13 In contrast to our study,
eradication of intestinal metaplasia was markedly diminished in patients treated with EMR
then RFA, with only 43% of those undergoing EMR/RFA achieving complete eradication of
intestinal metaplasia compared with 74% of those undergoing RFA alone. If, as suggested in
the previous study, only a minority of subjects achieve complete eradication of intestinal
metaplasia with EMR then RFA, then physicians might be more inclined to consider
surgical options for these patients with nodular BE. However, we found no difference in the
efficacy of RFA with or without prior EMR, suggesting that EMR then RFA is a suitable
primary therapeutic option for these patients. Additionally, in the previous Mayo study,
stricture formation was more frequent in the RFA after EMR group (13.6%) compared with
the RFA only group (8.7%), whereas in our study, no significant difference in stricture rate
was observed. The reasons for these differences are not entirely clear. However, unlike our
study, which featured only subjects with advanced neoplasia (HGD and IMC), most patients
in the previous study who had RFA only had non-dysplastic BE or low-grade dysplasia,
whereas almost all those undergoing EMR had more severe disease (89% either HGD or
IMC). Because degree of baseline dysplasia may be associated with decreased rates of
eradication or higher complication rates, these data may be confounded. The unbalanced
representation of advanced neoplasia may also contribute to the higher stricture rate
observed in the RFA after EMR group. Although multivariate analysis was performed in an
effort to account for these differences, the results are limited in their interpretability given
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the high degree of collinearity between the treatment used and the patients’ pre-treatment
histology, as well as the relatively small numbers of patients in the study.
In our study, patients who had EMR before RFA achieved CED in 94.0% and CEIM in
88.0% by intention to treat analysis. The rates of CED and CEIM in nodular disease treated
with RFA after EMR were similar to those achieved in patients undergoing RFA only for
non-nodular dysplasia. This suggests that treatment with EMR before RFA does not
diminish the efficacy of RFA. The differences in eradication rates between the two groups
were more significant in the ITT vs. PP analysis. For example, the ITT CED rates between
the two groups approached statistical significance (94.0% EMR/RFA vs. 82.7% RFA only;
p=0.06); however, this is largely attributable to the differential loss to follow-up between the
two groups (2 in EMR/RFA vs. 14 in RFA alone; p=0.09).
We also found that prior EMR was associated with a decreased number of circumferential
ablation sessions. Although it is unclear why the number of circumferential treatments was
less in subjects who underwent EMR before RFA therapy, one reasonable explanation is that
the initial EMR induced reversion of a substantial portion of the original BE segment to
neosquamous epithelium. Therefore, in subsequent treatment sessions, the endoscopist may
have opted to treat with the focal device due to the more limited nature of the residual
disease. This, however, is a hypothesis and cannot be confirmed without measurement of the
surface involvement of Barrett’s, which was not done in this retrospective study.
No difference in complication rate was observed between the two groups, suggesting that
undergoing EMR before RFA does not increase the risk of complication associated with
RFA. Stricture formation was not more common in those with EMR before RFA (4.6% of
patients) compared with patients treated with RFA alone (7.7% of patients). However, the
low number of complications in this cohort limits the conclusions that can be drawn
regarding differences in complication rates between the groups.
A significant number of subjects had resection with the Olympus cap and the Duette device.
However, due to the low number of complications in each of the EMR groups, our study
was unable to assert the superiority of one method over the other. It is the practice at our
institution to use the Olympus cap and snare when a single large resection is to be
performed, and the Duette band ligation device for either smaller resections or piecemeal
resections. Previous work demonstrates that the mucosal area resected with the cap and
snare device is somewhat larger than that of the banding device.21
There are several strengths to our study. This study represents the largest published cohort of
patients with BE and advanced neoplasia treated with EMR before RFA for nodular BE. By
limiting our study to only those subjects undergoing endoscopic therapy for either HGD or
IMC, we are able to more reasonably compare treatment groups with less concern of
confounding by baseline degree of dysplasia. Although a higher proportion of subjects who
underwent EMR then RFA had IMC than those that underwent RFA alone, confounding by
degree of dysplasia would only be expected to further strengthen our findings because more
severe disease was present at baseline in the EMR group. Another strength is that biopsy
samples were analyzed by expert gastrointestinal pathologists, with all dysplasia confirmed
by 2 readings.
Our study also had several limitations. This study was conducted at a tertiary-care referral
center. Endoscopies and interventions were performed by the same experienced
gastroenterologists. Therefore, whether or not these results can be generalized to community
practice settings is unknown. Also, almost all patients in this study had only 1 EMR
treatment session. Patients, however, may need treatment with more than 1 EMR session to
achieve non-nodular BE.13 Therefore, we cannot comment on the effects of more than one
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EMR session before RFA with respect to efficacy and safety of treatment. Additionally,
there were only 3 patients with IMC treated with RFA alone in our study, making it difficult
to draw conclusions about this subset of patients. Finally, despite our rigorous attempts at
complete collection of data, the retrospective nature of this study makes underestimation of
complications or misclassification errors possible.
In summary, RFA after EMR is a safe and effective treatment option for patients with
nodular BE and advanced neoplasia. In our cohort, the performance of EMR before RFA
was not associated with a diminished likelihood of success of therapy, or an increased rate
of stricture compared with those with advanced neoplasia undergoing RFA alone. Further
studies are necessary to determine the effects of EMR before RFA on the durability of RFA
treatment, and to determine the effects of multiple EMR sessions on RFA outcomes.
Acknowledgments
Grant Support: This research was supported by a grant from the Doris Duke Charitable Foundation to the
University of North Caroline-Chapel Hill (HPK), NIH P30 DK034987, and NIH T32 DK007634.
References
1. Cameron AJ, Souto EO, Smyrk TC. Small adenocarcinomas of the esophagogastric junction:
association with intestinal metaplasia and dysplasia. The American journal of gastroenterology.
2002; 97(6):1375–80. Epub 2002/07/04. [PubMed: 12094853]
2. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of
adenocarcinoma among patients with Barrett’s esophagus. The New England journal of medicine.
2011; 365(15):1375–83. Epub 2011/10/15. [PubMed: 21995385]
3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of
esophageal adenocarcinoma incidence. Journal of the National Cancer Institute. 2005; 97(2):142–6.
Epub 2005/01/20. [PubMed: 15657344]
4. Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal
adenocarcinoma in England and Wales. The American journal of gastroenterology. 2008; 103(11):
2694–9. Epub 2008/10/16. [PubMed: 18853967]
5. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency
ablation in Barrett’s esophagus with dysplasia. The New England journal of medicine. 2009;
360(22):2277–88. Epub 2009/05/29. [PubMed: 19474425]
6. Sharma VK, Jae Kim H, Das A, Wells CD, Nguyen CC, Fleischer DE. Circumferential and focal
ablation of Barrett’s esophagus containing dysplasia. The American journal of gastroenterology.
2009; 104(2):310–7. Epub 2009/01/29. [PubMed: 19174783]
7. Vassiliou MC, von Renteln D, Wiener DC, Gordon SR, Rothstein RI. Treatment of ultralong-
segment Barrett’s using focal and balloon-based radiofrequency ablation. Surgical endoscopy. 2010;
24(4):786–91. Epub 2009/08/28. [PubMed: 19711128]
8. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of
Barrett’s esophagus. The American journal of gastroenterology. 2008; 103(3):788–97. Epub
2008/03/18. [PubMed: 18341497]
9. Ortiz-Fernandez-Sordo J, Parra-Blanco A, Garcia-Varona A, Rodriguez-Pelaez M, Madrigal-Hoyos
E, Waxman I, et al. Endoscopic resection techniques and ablative therapies for Barrett’s neoplasia.
World journal of gastrointestinal endoscopy. 2011; 3(9):171–82. Epub 2011/09/29. [PubMed:
21954414]
10. Paris Workshop on Columnar Metaplasia in the Esophagus and the Esophagogastric Junction,
Paris, France, December 11-12 2004. Endoscopy. 2005; 37(9):879–920. Epub 2005/08/24.
[PubMed: 16116544]
11. Chennat J, Konda VJ, Ross AS, de Tejada AH, Noffsinger A, Hart J, et al. Complete Barrett’s
eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia
Kim et al. Page 8













and intramucosal carcinoma--an American single-center experience. The American journal of
gastroenterology. 2009; 104(11):2684–92. Epub 2009/08/20. [PubMed: 19690526]
12. Lewis JJ, Rubenstein JH, Singal AG, Elmunzer BJ, Kwon RS, Piraka CR. Factors associated with
esophageal stricture formation after endoscopic mucosal resection for neoplastic Barrett’s
esophagus. Gastrointestinal endoscopy. 2011; 74(4):753–60. Epub 2011/08/09. [PubMed:
21820109]
13. Okoro NI, Tomizawa Y, Dunagan KT, Lutzke LS, Wang KK, Prasad GA. Safety of Prior
Endoscopic Mucosal Resection in Patients Receiving Radiofrequency Ablation of Barrett’s
Esophagus. Clinical gastroenterology and hepatology : the official clinical practice journal of the
American Gastroenterological Association. 2011 Epub 2011/11/08.
14. Peters FP, Kara MA, Rosmolen WD, Aalders MC, Ten Kate FJ, Bultje BC, et al. Endoscopic
treatment of high-grade dysplasia and early stage cancer in Barrett’s esophagus. Gastrointestinal
endoscopy. 2005; 61(4):506–14. Epub 2005/04/07. [PubMed: 15812401]
15. Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk
factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade
intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008; 57(9):
1200–6. Epub 2008/05/08. [PubMed: 18460553]
16. Gondrie JJ, Pouw RE, Sondermeijer CM, Peters FP, Curvers WL, Rosmolen WD, et al. Effective
treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the
HALO system. Endoscopy. 2008; 40(5):370–9. Epub 2008/05/22. [PubMed: 18494132]
17. Gondrie JJ, Pouw RE, Sondermeijer CM, Peters FP, Curvers WL, Rosmolen WD, et al. Stepwise
circumferential and focal ablation of Barrett’s esophagus with high-grade dysplasia: results of the
first prospective series of 11 patients. Endoscopy. 2008; 40(5):359–69. Epub 2008/05/22.
[PubMed: 18494131]
18. Pouw RE, Gondrie JJ, Sondermeijer CM, ten Kate FJ, van Gulik TM, Krishnadath KK, et al.
Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without
endoscopic resection. Journal of gastrointestinal surgery : official journal of the Society for
Surgery of the Alimentary Tract. 2008; 12(10):1627–36. discussion 36-7. Epub 2008/08/16.
[PubMed: 18704598]
19. Pouw RE, Wirths K, Eisendrath P, Sondermeijer CM, Ten Kate FJ, Fockens P, et al. Efficacy of
radiofrequency ablation combined with endoscopic resection for barrett’s esophagus with early
neoplasia. Clinical gastroenterology and hepatology : the official clinical practice journal of the
American Gastroenterological Association. 2010; 8(1):23–9. Epub 2009/07/16. [PubMed:
19602454]
20. Herrero LA, van Vilsteren FG, Pouw RE, ten Kate FJ, Visser M, Seldenrijk CA, et al. Endoscopic
radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett’s
esophagus longer than 10 cm. Gastrointestinal endoscopy. 2011; 73(4):682–90. Epub 2011/02/05.
[PubMed: 21292262]
21. Pouw RE, van Vilsteren FG, Peters FP, Herrero LA, Ten Kate FJ, Visser M, et al. Randomized
trial on endoscopic resection-cap versus multiband mucosectomy for piecemeal endoscopic
resection of early Barrett’s neoplasia. Gastrointestinal endoscopy. 2011; 74(1):35–43. Epub
2011/06/28. [PubMed: 21704807]
Kim et al. Page 9

























Kim et al. Page 10
Table 1





Age – mean (SD) 68.8 (10.0) 64.2 (11.2) 0.008
Gender – no. males (%) 52 (80.0) 79 (76.0) 0.54
Race – no. Caucasian (%) 63 (96.9) 99 (95.2) 0.57
BMI – mean (SD) 30.2 (6.6) 29.1 (5.7) 0.22
Substance use
 Tobacco – no. (%) 12 (18.5) 27 (26.0) 0.28
 Alcohol – no. (%) 33 (50.8) 40 (38.5) 0.10
NSAID use – no. (%) 33 (50.8) 51 (49.0) 0.83
EGD findings
 Length of BE – mean (SD) 4.4 (3.1) 4.8 (3.4) 0.41
 Erosive esophagitis – no. (%) 5 (7.7) 2 (1.9) 0.07
 Hiatus hernia – no. (%) 58 (89.2) 93 (89.4) 0.81
Pre-ablation histology
 HGD – no. (%) 37 (56.9) 101 (97.1) <0.001
 IMC – no. (%) 28 (43.1) 3 (2.9)
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Table 2
Safety Outcomes
EMR before RFA RFA only p-value
Complications per Patient – no. (%)
N 65 104
Any complication 5 (7.7) 10 (9.6) 0.79
Stricture 3 (4.6) 8 (7.7) 0.53
Bleeding 2 (3.1) 2 (1.9) 0.64
Hospitalization* 2 (3.1) 2 (1.9) 0.64
Complications per Procedure – no. (%)
N 212 293
Any complication 5 (2.4) 10 (3.4) 0.60
Stricture 3 (1.4) 8 (2.7) 0.37
Bleeding 2 (0.9) 2 (0.7) 1.00
Hospitalization* 2 (0.9) 2 (0.7) 1.00
*
Hospitalizations were secondary to post-procedural hemorrhage
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Table 3
Efficacy Outcomes
EMR before RFA RFA only p-value
Intention-to-treat
N 50 98
CED 47 (94.0) 81 (82.7) 0.06
CEIM 44 (88.0) 76 (77.6) 0.13
Total treatment sessions, mean (SD) 3.5 (1.6) 2.8 (1.7) 0.02
RFA treatment sessions, mean (SD) 2.5 (1.5) 2.8 (1.6) 0.28
Per protocol
N 48 84
CED 47 (97.9) 81 (96.4) 0.63
CEIM 44 (91.7) 76 (90.5) 0.82
Total treatment sessions, mean (SD) 3.5 (1.6) 2.8 (1.5) 0.008
RFA treatment sessions, mean (SD) 2.5 (1.5) 2.7 (1.4) 0.44
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